Suzhou Furong Biotechnology

About Suzhou Furong Biotechnology

Suzhou Furong Biotechnology Co., Ltd. is a clinical-stage biotechnology company founded in April 2019, specializing in the development of next-generation cytokine therapeutics for oncology. The firm operates based on a synthetic immunology approach and has built four core technology platforms to address challenges in developing cytokine drugs. These platforms include the Fbody® Long-acting Technology Platform, an Fc engineering platform, the Syntokine® Synthetic Cytokine Platform, and an AI-driven Intelligent Biomolecular Discovery Platform. The company's founder and CEO is Dr. Tianlei Ying, who has over 15 years of immunology research experience and previously served as an Investigator at the National Cancer Institute (NCI) in the U.S. The CEO is Dr. Dong Wei, a seasoned executive with over 20 years in the global biotech industry, having held leadership roles at companies like EdiGene, Shire (now Takeda), and Johnson & Johnson. Forlong Biotechnology's business model centers on the independent research and development of innovative macromolecular drugs, particularly long-acting fusion protein therapies. The company generates revenue by creating engineered therapeutic cytokine combinations that target various stages of the cancer-immunity cycle. Its primary clients are patients with advanced solid tumors and other severe unmet medical needs. The lead asset in its pipeline is FL115, a super agonist of interleukin-15 (IL-15) designed to activate natural killer (NK) cells and memory T cells to fight cancer. FL115 has demonstrated a good safety profile and initial efficacy in clinical trials in both the United States and China for patients with advanced solid tumors. It is notably the only IL-15 super agonist to have achieved a partial response as a monotherapy. Other pipeline products include FL116, an engineered interleukin-18 (IL-18) that targets and activates T cells, and has shown potent tumor-killing effects in preclinical models resistant to immune checkpoint inhibitors. Since its founding, the company has achieved several key milestones. It raised an angel investment from Con-win Ventures in November 2021 and secured approximately $15 million in a Series A financing round led by Puhua Capital in February 2023. In May 2026, the company raised CNY 120 million in a pre-series B funding round to advance its clinical trials. Forlong Biotechnology is headquartered in Suzhou, China, a city aspiring to become a global biopharmaceutical hub. Keywords: cytokine therapeutics, synthetic immunology, oncology, cancer immunotherapy, interleukin-15, IL-15 superagonist, interleukin-18, fusion protein therapies, clinical-stage biotechnology, macromolecular drugs, Fbody platform, tumor immunology, advanced solid tumors, non-muscle-invasive bladder cancer, NK cells, memory T cells, immune checkpoint inhibitors, FL115, FL116, drug discovery, biopharmaceuticals, Forlong Biotechnology